Alnylam Pharmaceuticals
ALNY
595 hedge funds and large institutions have $30.1B invested in Alnylam Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 99 funds opening new positions, 239 increasing their positions, 180 reducing their positions, and 62 closing their positions.
60% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 62
33% more repeat investments, than reductions
Existing positions increased: 239 | Existing positions reduced: 180
17% more call options, than puts
Call options by funds: $195M | Put options by funds: $166M
5% more funds holding
Funds holding: 567 → 595 (+28)
2.58% more ownership
Funds ownership: 96.46% → 99.04% (+2.6%)
12% less capital invested
Capital invested by funds: $34.1B → $30.1B (-$3.99B)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$454M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$327M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$87.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$82.9M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$80.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$671M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$312M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$223M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$199M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$61.6M |
ALNY Hedge Fund Activity: Q4 2024 in Review
595 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2024, worth a combined $30.1B — down 12% from $34.1B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new ALNY positions and 62 closed out — a net gain of 37 holders — while 239 added to existing stakes and 180 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $454M. The largest seller was Capital International Investors, cutting an estimated $671M.
- 595 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2024, up from 567 in Q3 2024.
- Funds reported $30.1B of Alnylam Pharmaceuticals stock for Q4 2024, down 12% quarter-over-quarter.
- 99 funds opened new Alnylam Pharmaceuticals positions in Q4 2024 and 62 closed out, a net change of +37 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2024 was Capital Research Global Investors, an estimated $454M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2024 was Capital International Investors, an estimated $671M sold.
Based on aggregated 13F filings for Q4 2024.